Scotiabank Raises Eli Lilly Price Target to $1,605 From $1,300
Scotiabank maintained its Sector Outperform rating on Eli Lilly and raised its price target to $1,605 from $1,300.
Scotiabank maintained its Sector Outperform rating on Eli Lilly and raised its price target to $1,605 from $1,300.